Aytu Biopharma, Inc AYTU
Aytu Biopharma, Inc (Nasdaq: AYTU) is a CNS/neurology/psychiatry drug developer. Its lead program, EXXUA (gepirone) extended-release, is marketed for major depressive disorder in adults.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EXXUA (gepirone ER) | major depressive disorder | small molecule | Approved |
| Adzenys XR-ODT | ADHD | small molecule | Approved |
| Cotempla XR-ODT | ADHD | small molecule | Approved |
| Karbinal ER | seasonal and perennial allergies | small molecule | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.